<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="44185">Methotrexate</z:chebi> reduces intracellular pools of <z:chebi fb="0" ids="20612">5-methyltetrahydrofolate</z:chebi> and could result in reduced conversion of <z:chebi fb="0" ids="17230">homocysteine</z:chebi> to methionine by methionine synthetase </plain></SENT>
<SENT sid="1" pm="."><plain>This study was designed to investigate the effects of moderate dose to very high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> on methionine and total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> as reflections of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> induced intracellular events </plain></SENT>
<SENT sid="2" pm="."><plain>Methionine and total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> were measured prior to, during, and following twenty-six 24-h i.v. infusions of 33.6 g/m2 methotrexate (very high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>) in 16 children with <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> and seven 4-h i.v. infusions of 8 g/m2 methotrexate (high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi>) in 5 children with <z:hpo ids='HP_0002669'>osteogenic sarcoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Amino acids were measured by gas chromatography/mass spectrophotometry </plain></SENT>
<SENT sid="4" pm="."><plain>Mean methionine levels decreased by 70.0 +/- 3.1% (SE) with very high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and 72.6 +/- 5.9% with high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> at 24 and 4.5 h, respectively, after beginning <z:chebi fb="0" ids="44185">methotrexate</z:chebi> infusions </plain></SENT>
<SENT sid="5" pm="."><plain>Mean total <z:chebi fb="0" ids="17230">homocysteine</z:chebi> levels increased by 61.7 +/- 3.1% with very high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and 55.6 +/- 17.5% with high dose <z:chebi fb="0" ids="44185">methotrexate</z:chebi> at 36 and 24 h, respectively, after beginning <z:chebi fb="0" ids="44185">methotrexate</z:chebi> infusions </plain></SENT>
<SENT sid="6" pm="."><plain>No consistent or significant changes were noted in levels of total cysteine, leucine, isoleucine, or valine </plain></SENT>
<SENT sid="7" pm="."><plain>Similar changes did not occur in patients receiving <z:chebi fb="0" ids="8382">prednisone</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, daunomycin, and intrathecal <z:chebi fb="0" ids="44185">methotrexate</z:chebi> as therapy for <z:hpo ids='HP_0011009'>acute</z:hpo> lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>These changes in <z:chebi fb="0" ids="17230">homocysteine</z:chebi> and methionine may reflect biological effects of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> that may predict cytotoxicity of <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
</text></document>